1. Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation.
- Author
-
Albain KS, Le Beau MM, Ullirsch R, and Schumacher H
- Subjects
- Alkylating Agents adverse effects, Antibiotics, Antineoplastic adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms complications, Breast Neoplasms drug therapy, Breast Neoplasms therapy, Cisplatin adverse effects, Combined Modality Therapy, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Dactinomycin adverse effects, Doxorubicin administration & dosage, Doxorubicin adverse effects, Humans, Iatrogenic Disease, Leukemia, Monocytic, Acute classification, Leukemia, Monocytic, Acute genetics, Mastectomy, Radical, Middle Aged, Podophyllotoxin adverse effects, Radiotherapy, Tamoxifen administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chromosomes, Human, Pair 11 ultrastructure, Chromosomes, Human, Pair 9 ultrastructure, Leukemia, Monocytic, Acute chemically induced, Topoisomerase II Inhibitors, Translocation, Genetic
- Abstract
The present case, together with other reports reviewed herein, defines a new subtype of therapy-related acute myeloid leukemia (t-AML). This variant of t-AML is characterized by a short interval from initial drug therapy to bone marrow dysfunction and monocytic morphology without trilineage dysplasia. Unlike classic t-AML, which frequently has abnormalities of chromosomes 5 and/or 7, this new subtype is characterized by rearrangements involving band q23 of chromosome 11, most commonly a 9;11 translocation. The majority of patients with this subtype t-AML had prior cytotoxic therapy with topoisomerase II-reactive drugs including anthracyclines, epipodophyllotoxins, or actinomycin D, combined with either an alkylating agent or cisplatin. This association of prior therapy which includes topoisomerase II-reactive agents and a rapidly appearing t-AML involving the monocytic line and chromosome 11 requires additional study.
- Published
- 1990
- Full Text
- View/download PDF